You just read:

Six-Year Follow-Up Data for SPRYCEL®▼ (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib

News provided by

Bristol-Myers Squibb & Otsuka Pharmaceutical Europe Ltd.

15 Jun, 2012, 19:04 BST